Insider Selling: Natera (NASDAQ:NTRA) Insider Sells $1,082,725.92 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 4,692 shares of Natera stock in a transaction on Friday, December 12th. The shares were sold at an average price of $230.76, for a total value of $1,082,725.92. Following the completion of the transaction, the insider directly owned 113,065 shares of the company’s stock, valued at $26,090,879.40. This represents a 3.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Solomon Moshkevich also recently made the following trade(s):

• On Monday, December 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $238.15, for a total value of $714,450.00.
• On Monday, November 3rd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $198.60, for a total value of $595,800.00.
• On Tuesday, October 28th, Solomon Moshkevich sold 1,198 shares of Natera stock. The stock was sold at an average price of $191.46, for a total transaction of $229,369.08.
• On Monday, October 27th, Solomon Moshkevich sold 1,008 shares of Natera stock. The stock was sold at an average price of $192.32, for a total transaction of $193,858.56.
• On Tuesday, October 21st, Solomon Moshkevich sold 292 shares of Natera stock. The shares were sold at an average price of $187.95, for a total transaction of $54,881.40.
• On Wednesday, October 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $159.99, for a total transaction of $479,970.00.

Natera Trading Down 0.3%

NASDAQ NTRA opened at $224.74 on Friday. The firm has a market capitalization of $31.09 billion, a price-to-earnings ratio of -98.14 and a beta of 1.63. The firm’s 50 day simple moving average is $211.14 and its 200 day simple moving average is $178.40. Natera, Inc. has a 1 year low of $125.38 and a 1 year high of $246.90.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The firm had revenue of $592.18 million for the quarter, compared to analyst estimates of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The firm’s revenue for the quarter was up 34.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.26) earnings per share. On average, equities research analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on NTRA shares. Royal Bank Of Canada set a $268.00 price objective on Natera and gave the company an “outperform” rating in a research note on Tuesday, September 2nd. Stephens raised their price target on shares of Natera from $197.00 to $235.00 and gave the company an “overweight” rating in a research note on Thursday, November 13th. Evercore ISI upped their price objective on shares of Natera from $190.00 to $250.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a research note on Wednesday, October 8th. Finally, BNP Paribas Exane raised shares of Natera from an “underperform” rating to a “neutral” rating and set a $172.00 target price on the stock in a research note on Monday, October 27th. Fifteen investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $229.12.

Institutional Investors Weigh In On Natera

A number of institutional investors have recently added to or reduced their stakes in the business. Siemens Fonds Invest GmbH increased its holdings in Natera by 3.1% during the 3rd quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock worth $290,000 after acquiring an additional 54 shares during the period. Guided Capital Wealth Management LLC grew its position in shares of Natera by 0.5% during the 2nd quarter. Guided Capital Wealth Management LLC now owns 13,135 shares of the medical research company’s stock valued at $2,219,000 after purchasing an additional 66 shares in the last quarter. BOKF NA increased its holdings in shares of Natera by 1.9% in the third quarter. BOKF NA now owns 3,733 shares of the medical research company’s stock worth $601,000 after purchasing an additional 69 shares during the period. Silvant Capital Management LLC raised its position in shares of Natera by 0.5% in the third quarter. Silvant Capital Management LLC now owns 13,488 shares of the medical research company’s stock worth $2,171,000 after buying an additional 70 shares in the last quarter. Finally, Main Management ETF Advisors LLC raised its position in shares of Natera by 1.7% in the second quarter. Main Management ETF Advisors LLC now owns 4,398 shares of the medical research company’s stock worth $743,000 after buying an additional 72 shares in the last quarter. 99.90% of the stock is owned by institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.